ATE480521T1 - Stickstoff enthaltende heterocyclische verbindungen - Google Patents

Stickstoff enthaltende heterocyclische verbindungen

Info

Publication number: ATE480521T1
Authority: AT; Austria
Prior art keywords: substituted; atom; alkyl group; nitrogen atom; nitrogen
Prior art date: 1996-10-01

Application number

AT97943133T

Other languages

English (en)

Inventor

Kenji Matsuno

Michio Ichimura

Yuji Nomoto

Shigeki Fujiwara

Shinichi Ide

Eiji Tsukuda

Junko Irie

Shoji Oda

Original Assignee

Kyowa Hakko Kirin Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-10-01

Filing date

1997-10-01

Publication date

2010-09-15

1997-10-01 Application filed by Kyowa Hakko Kirin Co Ltd filed Critical Kyowa Hakko Kirin Co Ltd

2010-09-15 Application granted granted Critical

2010-09-15 Publication of ATE480521T1 publication Critical patent/ATE480521T1/de

Links

229910052757 nitrogen Inorganic materials 0.000 title abstract 5
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 title 2
150000002391 heterocyclic compounds Chemical class 0.000 title 1
125000000217 alkyl group Chemical group 0.000 abstract 5
125000004433 nitrogen atom Chemical group N* 0.000 abstract 4
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
-1 nitrogen-containing heterocyclic compounds Chemical class 0.000 abstract 3
125000002723 alicyclic group Chemical group 0.000 abstract 2
125000005843 halogen group Chemical group 0.000 abstract 2
206010003210 Arteriosclerosis Diseases 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
108091008606 PDGF receptors Proteins 0.000 abstract 1
102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 abstract 1
230000002159 abnormal effect Effects 0.000 abstract 1
208000011775 arteriosclerosis disease Diseases 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
230000010261 cell growth Effects 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
125000004093 cyano group Chemical group *C#N 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
206010061989 glomerulosclerosis Diseases 0.000 abstract 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
125000004430 oxygen atom Chemical group O* 0.000 abstract 1
230000026731 phosphorylation Effects 0.000 abstract 1
238000006366 phosphorylation reaction Methods 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
125000000547 substituted alkyl group Chemical group 0.000 abstract 1
229910052717 sulfur Inorganic materials 0.000 abstract 1
125000004434 sulfur atom Chemical group 0.000 abstract 1
230000002792 vascular Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/34—Phthalazines with nitrogen atoms directly attached to carbon atoms of the nitrogen-containing ring, e.g. hydrazine radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D317/58—Radicals substituted by nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Pyridine Compounds (AREA)
Quinoline Compounds (AREA)
Other In-Based Heterocyclic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

AT97943133T 1996-10-01 1997-10-01 Stickstoff enthaltende heterocyclische verbindungen ATE480521T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP26074396		1996-10-01
PCT/JP1997/003510 WO1998014431A1 (en)	1996-10-01	1997-10-01	Nitrogenous heterocyclic compounds

Publications (1)

Publication Number	Publication Date
ATE480521T1 true ATE480521T1 (de)	2010-09-15

Family

ID=17352137

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT97943133T ATE480521T1 (de)	1996-10-01	1997-10-01	Stickstoff enthaltende heterocyclische verbindungen

Country Status (13)

Country	Link
US (4)	US6169088B1 (de)
EP (1)	EP0882717B1 (de)
JP (1)	JP4073961B2 (de)
KR (1)	KR100622323B1 (de)
CN (1)	CN1169795C (de)
AT (1)	ATE480521T1 (de)
AU (1)	AU719392B2 (de)
CA (1)	CA2239227C (de)
DE (1)	DE69739986D1 (de)
DK (1)	DK0882717T3 (de)
ES (1)	ES2351684T3 (de)
NZ (1)	NZ330571A (de)
WO (1)	WO1998014431A1 (de)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69720965T2 (de)	1996-02-13	2004-02-05	Astrazeneca Ab	Chinazolinderivate und deren verwendung als vegf hemmer
NZ331191A (en)	1996-03-05	2000-03-27	Zeneca Ltd	4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
GB9718972D0 (en)	1996-09-25	1997-11-12	Zeneca Ltd	Chemical compounds
WO1998013350A1 (en)	1996-09-25	1998-04-02	Zeneca Limited	Qinoline derivatives inhibiting the effect of growth factors such as vegf
EP1067123B1 (de) *	1998-03-31	2011-01-19	Kyowa Hakko Kirin Co., Ltd.	Stickstoffenthaltende heterocyclische verbindungen
US6184226B1 (en) *	1998-08-28	2001-02-06	Scios Inc.	Quinazoline derivatives as inhibitors of P-38 α
US7262201B1 (en)	1998-10-08	2007-08-28	Astrazeneca Ab	Quinazoline derivatives
UA71945C2 (en)	1999-01-27	2005-01-17	Pfizer Prod Inc	Substituted bicyclic derivatives being used as anticancer agents
JP3270834B2 (ja)	1999-01-27	2002-04-02	ファイザー・プロダクツ・インク	抗がん剤として有用なヘテロ芳香族二環式誘導体
US6455734B1 (en) *	2000-08-09	2002-09-24	Magnesium Diagnostics, Inc.	Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
GB9919558D0 (en) *	1999-08-18	1999-10-20	Hoechst Schering Agrevo Gmbh	Fungicidal compounds
JP2001131151A (ja) *	1999-11-02	2001-05-15	Shionogi & Co Ltd	オレフィン誘導体の新規用途
KR100881105B1 (ko)	1999-11-05	2009-02-02	아스트라제네카 아베	Ｖｅｇｆ 억제제로서의 퀴나졸린 유도체
ES2267748T3 (es)	2000-04-07	2007-03-16	Astrazeneca Ab	Compuestos de quinazolina.
KR100774855B1 (ko) *	2000-04-27	2007-11-08	아스텔라스세이야쿠 가부시키가이샤	축합 헤테로아릴 유도체
US6608053B2 (en)	2000-04-27	2003-08-19	Yamanouchi Pharmaceutical Co., Ltd.	Fused heteroaryl derivatives
EP1290028B1 (de)	2000-06-05	2009-12-23	The Brigham And Women's Hospital, Inc.	Für ein homologes des humanen, für mehrfachresistenz verantwortlichen, p-glykoproteins auf chromosom 7p15-21 kodierendes gen sowie verwendungen dafür
WO2001095856A2 (en) *	2000-06-15	2001-12-20	Chaconne Nsi Co., Ltd.	Urea derivative useful as an anti-cancer agent and process for preparing same
EP1301484A2 (de) *	2000-07-20	2003-04-16	Neurogen Corporation	Capsaicin-rezeptor-liganden
WO2002012228A1 (en)	2000-08-09	2002-02-14	Astrazeneca Ab	Cinnoline compounds
WO2002012226A1 (en)	2000-08-09	2002-02-14	Astrazeneca Ab	Quinoline derivatives having vegf inhibiting activity
DE60143204D1 (de) *	2000-08-18	2010-11-18	Kyowa Hakko Kirin Co Ltd	N-aryl-ä4-Ä7-(alkoxy)Chinazolin-4-ylÜPiperazinylüCarboxamid-Verbindungen als PDGF-Rezeptoren Hemmer
AU2001293208A1 (en) *	2000-08-18	2002-03-04	Cor Therapeutics, Inc.	Nitrogenous heterocyclic compounds
EP1309567A2 (de) *	2000-08-18	2003-05-14	Millennium Pharmaceuticals, Inc.	Stickstoffhaltige heterozyklische verbindungen
PT1315715E (pt) *	2000-08-18	2008-10-30	Millennium Pharm Inc	Derivados de quianazolina utilizados como inibidores de quinase
JP4564713B2 (ja)	2000-11-01	2010-10-20	ミレニアム・ファーマシューティカルズ・インコーポレイテッド	窒素性複素環式化合物、ならびに窒素性複素環式化合物およびその中間体を作製するための方法
US20040259881A1 (en) *	2001-02-02	2004-12-23	Anjali Pandey	Nitrogenous heterocyclic compounds
MXPA03007609A (es) *	2001-02-27	2004-06-30	Univ Michigan	Uso de inhibidores egfr naturales para evitar efectos secundarios debidos a terapia de retinoide, jabones y otros estimulos que activan el receptor del factor de crecimiento epidermico.
WO2002072578A2 (en) *	2001-03-08	2002-09-19	Millennium Pharmaceuticals	(homo) piperazine substituted quinolines for inhibiting the phosphorylation of kinases
US6896949B1 (en)	2001-03-15	2005-05-24	Bookham (Us) Inc.	Wafer scale production of optical elements
JP3715280B2 (ja) *	2001-05-21	2005-11-09	エフ．ホフマン−ラロシュアーゲー	ニューロペプチドｙレセプターのリガンドとしてのキノリン誘導体
US8124625B2 (en)	2001-09-14	2012-02-28	Shionogi & Co., Ltd.	Method of enhancing the expression of apolipoprotein AI using olefin derivatives
US6787558B2 (en)	2001-09-28	2004-09-07	Hoffmann-La Roche Inc.	Quinoline derivatives
ITMI20012060A1 (it) *	2001-10-05	2003-04-05	Recordati Chem Pharm	Nuovi eterocilcli n-acilati
US7030115B2 (en)	2002-03-21	2006-04-18	Abbott Laboratories	N-sulfonylurea apoptosis promoters
WO2003080586A1 (en) *	2002-03-21	2003-10-02	Abbott Laboratories	N-sulfonylurea apoptosis promoters
BR0312204A (pt)	2002-06-27	2005-04-26	Schering Ag	Antagonista de receptor ccr5 de quinolina substituìda
CL2004000409A1 (es)	2003-03-03	2005-01-07	Vertex Pharma	Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu
US7713983B2 (en)	2003-03-03	2010-05-11	Vertex Pharmaceuticals Incorporated	Quinazolines useful as modulators of ion channels
NZ592039A (en)	2003-08-27	2013-03-28	Ophthotech Corp	Combination therapy for the treatment of ocular neovascular disorders
EP2210607B1 (de) *	2003-09-26	2011-08-17	Exelixis Inc.	N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamid zur Behandlung von Krebs
JP4845736B2 (ja) *	2003-10-14	2011-12-28	アリゾナボードオブリージェンツオンビハーフザユニバーシティーオブアリゾナ	プロテインキナーゼ阻害剤
US20090099165A1 (en)	2003-10-14	2009-04-16	Arizona Board Of Regents On Behalf Of The University Of Arizona	Protein Kinase Inhibitors
WO2005097134A2 (en) *	2004-03-31	2005-10-20	The Scripps Research Institute	Quinazoline based protein kinase inhibitors
US7928107B2 (en)	2004-09-02	2011-04-19	Vertex Pharmaceuticals Incorporated	Quinazolines useful as modulators of ion channels
CA2578996A1 (en) *	2004-09-03	2006-03-16	Memory Pharmaceuticals Corporation	4-substituted 4, 6-dialkoxy-cinnoline derivatives as phospodiesterase 10 inhibitors for the treatment of psychiatric or neurological syndroms
GB0503056D0 (en) *	2005-02-14	2005-03-23	Smithkline Beecham Corp	Chemical compounds
RU2007131400A (ru)	2005-03-01	2009-04-10	Вайет (Us)	Соединения циннолина и их применение в качестве модуляторов х-рецепторов печени
WO2006104971A1 (en) *	2005-03-28	2006-10-05	Bristol-Myers Squibb Company	Atp competitive kinase inhibitors
CA2604284A1 (en) *	2005-04-28	2006-11-02	Supergen, Inc.	Protein kinase inhibitors
US8071768B2 (en)	2005-06-10	2011-12-06	Janssen Pharmaceutica, N.V.	Alkylquinoline and alkylquinazoline kinase modulators
US7825244B2 (en)	2005-06-10	2010-11-02	Janssen Pharmaceutica Nv	Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis
EP1904459A1 (de) *	2005-07-20	2008-04-02	Millennium Pharmaceuticals, Inc.	Neue kristalline formen von 4-[6-methoxy-7-(3-piperidin-1-yl-propoxy)chinazolin-4-yl]piperazin-1-carboxylsäure(4-isopropoxyphenyl)-amid
AU2013211455B2 (en) *	2005-09-19	2017-12-07	Neuronascent, Inc.	Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration
CA2643963A1 (en) *	2006-02-21	2007-08-30	Amgen Inc.	Cinnoline derivatives as phosphodiesterase 10 inhibitors
WO2007098214A1 (en) *	2006-02-21	2007-08-30	Amgen Inc.	Cinnoline derivatives as phosphodiesterase 10 inhibitors
US20070287707A1 (en) *	2006-02-28	2007-12-13	Arrington Mark P	Phosphodiesterase 10 inhibitors
US20090099175A1 (en) *	2006-03-01	2009-04-16	Arrington Mark P	Phosphodiesterase 10 inhibitors
WO2007103554A1 (en) *	2006-03-08	2007-09-13	Amgen Inc.	Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors
US8106071B2 (en) *	2007-02-21	2012-01-31	Biobud Co., Ltd.	Compositions for treating hyperproliferative vascular disorders and cancers
EP2139869A2 (de) *	2007-04-13	2010-01-06	SuperGen, Inc.	Axl-kinasehemmer
MX2011004683A (es) *	2008-11-03	2011-06-20	Lilly Co Eli	Antagonistas de la via hedgehog de ftalazina disustituida.
JP2012509321A (ja) *	2008-11-21	2012-04-19	ミレニアムファーマシューティカルズ，インコーポレイテッド	癌および他の疾患または障害の処置のための、４−［６−メトキシ−７−（３−ピペリジン−１−イル−プロポキシ）キナゾリン−４−イル］ピペラジン−１−カルボン酸（４−イソプロポキシフェニル）−アミドの乳酸塩およびその薬学的組成物
NZ779754A (en)	2009-01-16	2023-04-28	Exelixis Inc	Malate salt of n-(4-{ [6,7-bis(methyloxy)quinolin-4-yl] oxy} phenyl)-n’-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
WO2010099139A2 (en)	2009-02-25	2010-09-02	Osi Pharmaceuticals, Inc.	Combination anti-cancer therapy
WO2010099364A2 (en)	2009-02-27	2010-09-02	Osi Pharmaceuticals, Inc.	Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099138A2 (en)	2009-02-27	2010-09-02	Osi Pharmaceuticals, Inc.	Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099363A1 (en)	2009-02-27	2010-09-02	Osi Pharmaceuticals, Inc.	Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
UA108618C2 (uk)	2009-08-07	2015-05-25		Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
EP2518064A1 (de) *	2009-12-25	2012-10-31	Mochida Pharmaceutical Co., Ltd.	Neues arylharnstoffderivat
WO2012149014A1 (en)	2011-04-25	2012-11-01	OSI Pharmaceuticals, LLC	Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
EP3812387A1 (de)	2011-07-21	2021-04-28	Sumitomo Dainippon Pharma Oncology, Inc.	Heterocyclische proteinkinase-hemmer
EP2771011A4 (de)	2011-10-24	2015-04-15	Glaxosmithkline Ip No 2 Ltd	Chemische verbindungen
WO2013152252A1 (en)	2012-04-06	2013-10-10	OSI Pharmaceuticals, LLC	Combination anti-cancer therapy
PL2922845T3 (pl) *	2012-11-20	2018-11-30	Merial, Inc.	Związki przeciwrobacze oraz ich kompozycje i sposób stosowania
CN103601722B (zh) *	2013-09-13	2016-03-02	南京华威医药科技开发有限公司	新型抗肿瘤化合物
MA41169A (fr) *	2014-12-17	2017-10-24	Acraf	Composés antibactériens à large spectre d'activité
AU2017238758B2 (en) *	2016-03-21	2021-01-21	Council Of Scientific & Industrial Research	Blocking toll-like receptor 9 signaling with small molecule antagonist
CN108191756B (zh) *	2017-12-12	2020-08-25	绍兴文理学院	一种喹啉衍生物及其制备方法和应用
KR20210003780A (ko)	2018-04-05	2021-01-12	스미토모 다이니폰 파마 온콜로지, 인크.	Axl 키나제 억제제 및 그의 용도
KR20260008165A (ko)	2019-02-12	2026-01-15	스미토모 파마 아메리카, 인크.	헤테로시클릭 단백질 키나제 억제제를 포함하는 제제
CN112300082B (zh) *	2019-07-26	2022-04-26	暨南大学	一种苯基哌嗪喹唑啉类化合物或其药学上可接受的盐、制法与用途
WO2021020902A1 (ko) *	2019-07-30	2021-02-04	주식회사 하임바이오	신규한 항암용 화합물, 및 이를 유효성분으로 포함하는 약학조성물
WO2023280317A1 (zh) *	2021-07-09	2023-01-12	南京明德新药研发有限公司	苄氨基三并环类化合物及其应用
CN115677702B (zh) *	2021-07-23	2024-07-02	武汉誉祥医药科技有限公司	三并环化合物及其药物组合物和应用
CN117482096A (zh) *	2023-11-17	2024-02-02	右江民族医学院附属医院	Lf3在制备治疗关节炎药物中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3723434A (en) *	1970-07-17	1973-03-27	Pfizer	Piperazino isoquinoline bronchodilators
JPS58172379A (ja) *	1982-04-02	1983-10-11	Showa Denko Kk	新規なキナゾリン誘導体
JPS60120872A (ja) *	1983-12-01	1985-06-28	Kyowa Hakko Kogyo Co Ltd	新規なヘテロ環状化合物及び強心剤
JPH02167277A (ja) *	1988-09-19	1990-06-27	Kyowa Hakko Kogyo Co Ltd	新規なジアジン化合物
SG64322A1 (en) *	1991-05-10	1999-04-27	Rhone Poulenc Rorer Int	Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
JP3229693B2 (ja) *	1993-02-22	2001-11-19	協和醗酵工業株式会社	ピペラジン誘導体
WO1995006648A1 (fr) *	1993-09-03	1995-03-09	Kyowa Hakko Kogyo Co., Ltd.	Derive d'imidazoquinazoline
FR2722788B1 (fr) *	1994-07-20	1996-10-04	Pf Medicament	Nouvelles piperazides derivees d'aryl piperazine, leurs procedes de preparation, leur utilisation a titre de medicament et les compositions pharmaceutiques les comprenant
GB9510757D0 (en) *	1994-09-19	1995-07-19	Wellcome Found	Therapeuticaly active compounds
US5701492A (en) *	1996-03-29	1997-12-23	Canon Kabushiki Kaisha	Fail-safe flashing of EPROM

1997
- 1997-10-01 EP EP97943133A patent/EP0882717B1/de not_active Expired - Lifetime
- 1997-10-01 AT AT97943133T patent/ATE480521T1/de active
- 1997-10-01 JP JP51638098A patent/JP4073961B2/ja not_active Expired - Fee Related
- 1997-10-01 NZ NZ330571A patent/NZ330571A/xx not_active IP Right Cessation
- 1997-10-01 CN CNB971917418A patent/CN1169795C/zh not_active Expired - Fee Related
- 1997-10-01 AU AU44708/97A patent/AU719392B2/en not_active Ceased
- 1997-10-01 ES ES97943133T patent/ES2351684T3/es not_active Expired - Lifetime
- 1997-10-01 WO PCT/JP1997/003510 patent/WO1998014431A1/ja not_active Ceased
- 1997-10-01 CA CA002239227A patent/CA2239227C/en not_active Expired - Fee Related
- 1997-10-01 DK DK97943133.5T patent/DK0882717T3/da active
- 1997-10-01 KR KR1019980704125A patent/KR100622323B1/ko not_active Expired - Fee Related
- 1997-10-01 DE DE69739986T patent/DE69739986D1/de not_active Expired - Lifetime
1998
- 1998-06-01 US US09/088,199 patent/US6169088B1/en not_active Expired - Lifetime
2000
- 2000-01-12 US US09/481,544 patent/US6207667B1/en not_active Expired - Lifetime
- 2000-12-13 US US09/734,918 patent/US6472391B2/en not_active Expired - Lifetime
2002
- 2002-08-26 US US10/227,302 patent/US6750218B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US6207667B1 (en)	2001-03-27
CN1169795C (zh)	2004-10-06
JP4073961B2 (ja)	2008-04-09
DE69739986D1 (de)	2010-10-21
CA2239227A1 (en)	1998-04-09
HK1016174A1 (en)	1999-10-29
NZ330571A (en)	1999-10-28
EP0882717B1 (de)	2010-09-08
KR19990071843A (ko)	1999-09-27
DK0882717T3 (da)	2010-12-13
US6750218B2 (en)	2004-06-15
CA2239227C (en)	2007-10-30
AU4470897A (en)	1998-04-24
EP0882717A1 (de)	1998-12-09
ES2351684T3 (es)	2011-02-09
CN1208404A (zh)	1999-02-17
US20020068734A1 (en)	2002-06-06
EP0882717A4 (de)	2002-06-19
US6472391B2 (en)	2002-10-29
AU719392B2 (en)	2000-05-11
US6169088B1 (en)	2001-01-02
WO1998014431A1 (en)	1998-04-09
US20030229077A1 (en)	2003-12-11
KR100622323B1 (ko)	2006-11-30

Legal Events

Date

Code

Title

Description

2011-03-15

UEP

Publication of translation of european patent specification

Ref document number: 0882717

Country of ref document: EP

Publication	Publication Date	Title
DE69739986D1 (de)	2010-10-21	Stickstoff enthaltende heterocyclische verbindungen
ATE496035T1 (de)	2011-02-15	Stickstoffenthaltende heterocyclische verbindungen
ATE206412T1 (de)	2001-10-15	Heterocyclische verbindungen als bradykinin antagonisten
ATE541833T1 (de)	2012-02-15	Stickstoff-enthaltende verbindungen mit kinasehemmender wirkung sowie diese enthaltende medikamente
ATE123771T1 (de)	1995-06-15	Stickstoff enthaltende heterozyklische verbindungen, ihre herstellung und verwendung.
BR9408442A (pt)	1997-08-05	Composto composição farmacêutica processos para tratamento ou prevenção de distúrbios fisiológicos associados com um excesso de taquiquininas e para a preparação do composto e de uso do composto
HUP0001446A2 (hu)	2001-05-28	HIV reverz transzkriptáz inhibitor hatású 4,4-diszubsztituált-3,4-dihidro-2(1H)-kinazolinon-származékok, alkalmazásuk és a vegyületeket tartalmazó gyógyszerkészítmények
ATE105554T1 (de)	1994-05-15	Benzazol-derivate, verfahren zu deren herstellung und pharmazeutische zusammensetzungen, die sie enthalten.
DE69015239D1 (de)	1995-02-02	Chinolinon-Derivate, Verfahren zu ihrer Herstellung und diese Derivate enthaltende antibakteriell wirkende Mittel.
DE3750111D1 (de)	1994-07-28	Substituierte Phenyl-2-propensäure Derivate und ihre Verwendung als Fungizide.
ATE186301T1 (de)	1999-11-15	An den positionen 2 und 9 substituierte 4h-pyrido-(1,2-a)pyrimidin-4-one
ES2091489T3 (es)	1996-11-01	Derivados de imidazol y composiciones farmaceuticas que los contienen.
ATE147625T1 (de)	1997-02-15	Hydantoin- oder imidazolidintrionderivate zur vorbeugung oder behandlung von niereninsuffizienz
DE69416235D1 (de)	1999-03-11	Triazin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung
DE69814800D1 (de)	2003-06-26	Epoxysuccinamid-derivate oder ihre salze
DE3764077D1 (de)	1990-09-06	Zentralwirkende muskelrelaxante.
EP0798298A4 (de)	1998-03-25	Thiazolidinon-verbindungen oder heilmittel oder vorbeugemittel zur behandlung von angina pectoris das diese als wirkstoffe enthält
ATE205209T1 (de)	2001-09-15	Chinolincarbonsäurederivate und ihre salze
EP0299076A4 (en)	1991-01-09	5-hydroxyindole-3-carboxamide compound and medicinal use thereof
ES2084120T3 (es)	1996-05-01	Medicamentos para prevenir y tratar enfermedades del aparato circulatorio que contienen compuestos de espiro-3-heteroazolidina.
EP0990645A4 (de)	2002-01-02	Neue sulfonamid-derivate
ATE27455T1 (de)	1987-06-15	Heterocyclische guanidino-phenylamidine, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung.
ES8305350A1 (es)	1983-04-01	"un procedimiento para preparar derivados de dialcohilpirazol".
ES2118151T3 (es)	1998-09-16	Derivados de pirazolo(3,4-a)acridina como analgesicos.
TH18165A (th)	1996-04-19	สารยับยั้งการเกิดคีโมแทกซิของอีโอซีโนฟีล